PL3829628T3 - Kompozycja farmaceutyczna do zastosowania w leczeniu lub zapobieganiu chorobie związanej z C5 - Google Patents
Kompozycja farmaceutyczna do zastosowania w leczeniu lub zapobieganiu chorobie związanej z C5Info
- Publication number
- PL3829628T3 PL3829628T3 PL19755447.0T PL19755447T PL3829628T3 PL 3829628 T3 PL3829628 T3 PL 3829628T3 PL 19755447 T PL19755447 T PL 19755447T PL 3829628 T3 PL3829628 T3 PL 3829628T3
- Authority
- PL
- Poland
- Prior art keywords
- prevention
- treatment
- pharmaceutical composition
- related disease
- disease
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862713211P | 2018-08-01 | 2018-08-01 | |
US201862764952P | 2018-08-17 | 2018-08-17 | |
US201862760204P | 2018-11-13 | 2018-11-13 | |
PCT/JP2019/030283 WO2020027279A1 (en) | 2018-08-01 | 2019-08-01 | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3829628T3 true PL3829628T3 (pl) | 2024-08-19 |
Family
ID=67660420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL19755447.0T PL3829628T3 (pl) | 2018-08-01 | 2019-08-01 | Kompozycja farmaceutyczna do zastosowania w leczeniu lub zapobieganiu chorobie związanej z C5 |
Country Status (21)
Country | Link |
---|---|
US (1) | US20210301004A1 (pl) |
EP (2) | EP3829628B1 (pl) |
JP (3) | JP6672516B2 (pl) |
KR (5) | KR20200033225A (pl) |
CN (1) | CN112512563A (pl) |
AU (2) | AU2019315213B2 (pl) |
BR (1) | BR112021001655A2 (pl) |
CA (1) | CA3107618A1 (pl) |
CR (1) | CR20210103A (pl) |
DE (1) | DE112019003835T5 (pl) |
ES (1) | ES2980137T3 (pl) |
HR (1) | HRP20240823T1 (pl) |
HU (1) | HUE067057T2 (pl) |
IL (1) | IL280475A (pl) |
MX (1) | MX2021000516A (pl) |
PH (1) | PH12021550226A1 (pl) |
PL (1) | PL3829628T3 (pl) |
RS (1) | RS65630B1 (pl) |
SG (1) | SG10202002898RA (pl) |
TW (2) | TWI701041B (pl) |
WO (1) | WO2020027279A1 (pl) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
TR201808046T4 (tr) | 2008-04-11 | 2018-06-21 | Chugai Pharmaceutical Co Ltd | İki veya daha fazla sayıda antijen molekülüne tekrar tekrar bağlanabilen antijen bağlanma molekülü. |
RU2642318C2 (ru) | 2010-11-30 | 2018-01-24 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул |
HUE056489T2 (hu) | 2014-12-19 | 2022-02-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
ATE449791T1 (de) | 2000-10-10 | 2009-12-15 | Genentech Inc | Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung |
PT1425042E (pt) | 2001-08-17 | 2007-07-11 | Tanox Inc | Inibidores de via complementar que se ligam a c5a sem impedir a formação de c5b |
ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
SG2013036975A (en) | 2002-12-16 | 2016-07-28 | Genentech Inc | Immunoglobulin variants and uses thereof |
US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
ES2403055T3 (es) | 2004-04-13 | 2013-05-13 | F. Hoffmann-La Roche Ag | Anticuerpos anti-P-selectina |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
TR201808046T4 (tr) | 2008-04-11 | 2018-06-21 | Chugai Pharmaceutical Co Ltd | İki veya daha fazla sayıda antijen molekülüne tekrar tekrar bağlanabilen antijen bağlanma molekülü. |
PL2328616T3 (pl) | 2008-08-05 | 2015-10-30 | Novartis Ag | Kompozycje i sposoby dla przeciwciał celujących białko dopełniacza C5 |
ES2940466T3 (es) | 2008-11-10 | 2023-05-08 | Alexion Pharma Inc | Métodos y composiciones para tratar trastornos asociados al complemento |
CA2792740A1 (en) | 2010-03-11 | 2011-09-15 | Rinat Neuroscience Corporation | Antibodies with ph dependent antigen binding |
TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
RU2018125515A (ru) * | 2013-01-31 | 2018-10-29 | СЕУЛ НЭШНЛ ЮНИВЕРСИТИ Ар энд ДиБи ФАУНДЕЙШН | Антитело против c5 и способ предупреждения и лечения обусловленных комплементом заболеваний |
HUE056489T2 (hu) * | 2014-12-19 | 2022-02-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
JP6130983B2 (ja) * | 2015-02-27 | 2017-05-17 | 中外製薬株式会社 | Il−6関連疾患治療用組成物 |
US20190023775A1 (en) * | 2016-01-11 | 2019-01-24 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
WO2017132259A1 (en) | 2016-01-25 | 2017-08-03 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
US12128101B2 (en) * | 2017-10-26 | 2024-10-29 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) |
RU2020117578A (ru) * | 2017-12-04 | 2022-01-14 | Ра Фармасьютикалз, Инк. | Модуляторы активности комплемента |
-
2019
- 2019-08-01 KR KR1020197036896A patent/KR20200033225A/ko active Application Filing
- 2019-08-01 EP EP19755447.0A patent/EP3829628B1/en active Active
- 2019-08-01 MX MX2021000516A patent/MX2021000516A/es unknown
- 2019-08-01 TW TW108127358A patent/TWI701041B/zh active
- 2019-08-01 BR BR112021001655-4A patent/BR112021001655A2/pt unknown
- 2019-08-01 ES ES19755447T patent/ES2980137T3/es active Active
- 2019-08-01 US US17/263,691 patent/US20210301004A1/en active Pending
- 2019-08-01 PL PL19755447.0T patent/PL3829628T3/pl unknown
- 2019-08-01 DE DE112019003835.4T patent/DE112019003835T5/de active Pending
- 2019-08-01 CA CA3107618A patent/CA3107618A1/en active Pending
- 2019-08-01 HU HUE19755447A patent/HUE067057T2/hu unknown
- 2019-08-01 AU AU2019315213A patent/AU2019315213B2/en active Active
- 2019-08-01 WO PCT/JP2019/030283 patent/WO2020027279A1/en active Application Filing
- 2019-08-01 CN CN201980051238.8A patent/CN112512563A/zh active Pending
- 2019-08-01 KR KR1020217009235A patent/KR20210037743A/ko not_active IP Right Cessation
- 2019-08-01 KR KR1020247023205A patent/KR20240115904A/ko active Search and Examination
- 2019-08-01 KR KR1020207007296A patent/KR20200033348A/ko active Application Filing
- 2019-08-01 TW TW109108378A patent/TWI704157B/zh active
- 2019-08-01 JP JP2019142108A patent/JP6672516B2/ja active Active
- 2019-08-01 HR HRP20240823TT patent/HRP20240823T1/hr unknown
- 2019-08-01 KR KR1020217009233A patent/KR20210038697A/ko not_active IP Right Cessation
- 2019-08-01 EP EP24174873.0A patent/EP4445913A2/en active Pending
- 2019-08-01 CR CR20210103A patent/CR20210103A/es unknown
- 2019-08-01 SG SG10202002898RA patent/SG10202002898RA/en unknown
- 2019-08-01 RS RS20240695A patent/RS65630B1/sr unknown
-
2020
- 2020-02-18 JP JP2020025071A patent/JP6672533B1/ja active Active
- 2020-03-04 JP JP2020036818A patent/JP2020079331A/ja active Pending
-
2021
- 2021-01-28 IL IL280475A patent/IL280475A/en unknown
- 2021-01-29 PH PH12021550226A patent/PH12021550226A1/en unknown
-
2024
- 2024-08-02 AU AU2024205486A patent/AU2024205486A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3577135T3 (pl) | Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 | |
ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
RS65630B1 (sr) | Farmaceutska kompozicija za upotrebu u lečenju ili prevenciji bolesti povezane sa c5 | |
ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
IL279397A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
IL274578A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
IL281585B (en) | Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use | |
IL276323A (en) | 4-Methyldihydropyrimidinone compounds and their pharmaceutical use | |
IL272495A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
EP3785715C0 (en) | PHARMACEUTICAL COMPOSITION COMPRISING IBRUTINIB FOR USE IN THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE | |
IL268131A (en) | A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of alzheimer's disease | |
EP3338771A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF TRAMADOL-ETORICOXIB CHLORHYDRATE FOR THE TREATMENT OF PAIN | |
PL4072532T3 (pl) | Postać dawkowania do zastosowania w leczeniu lub zapobieganiu chorobie | |
PT3586832T (pt) | Composição farmacêutica para o tratamento da obstipação | |
PL3352777T3 (pl) | Engrailed do stosowania w leczeniu uszkodzenia dna u pacjentów cierpiących na chorobę parkinsona | |
GB201817346D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of diseases | |
GB201718838D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
RS64967B1 (sr) | Kompozicija za upotrebu u prevenciji i/ili lečenju osteoartikularnih bolesti | |
GB201712742D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
GB201814764D0 (en) | Pharmaceutical compositions for the treatment of proteinopathies | |
GB201911821D0 (en) | Compounds for use in the treatment of liver disease | |
GB201808464D0 (en) | Pharmaceutical compounds for use in treating huntington's disease | |
GB201817343D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
GB201817344D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
GB201720101D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |